GO
Loading...

Questcor Pharmaceuticals Inc

More

  • MS drug sales drive Questcor profit Thursday, 24 Jul 2014 | 9:28 AM ET

    July 24- Questcor Pharmaceuticals Inc posted a 39.5 percent rise in quarterly profit, helped by strong sales of multiple sclerosis drug Acthar. The company's net income rose to $96.4 million, or $1.54 per share, in the second quarter ended June 30, from $69.1 million, or $1.12 per share, a year earlier. Revenue jumped 51 percent to $278.8 million.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • FACTBOX-M&A frenzy transforming global pharma Tuesday, 6 May 2014 | 2:00 PM ET

    MAY May 6- Merck& Co Inc agrees to sell its consumer care business to Germany's Bayer AG for $14.2 billion. May 2- Pfizer Inc raises its offer for AstraZeneca Plc to 63 billion pounds, but the British company promptly rejects the proposal, which would create the world's biggest pharmaceuticals company.

  • FACTBOX-M&A frenzy in healthcare sector Tuesday, 29 Apr 2014 | 2:25 PM ET

    **U.S. drugmaker Pfizer said on April 28 that it had offered to buy Britain's AstraZeneca Plc in January for about $98.9 billion, or nearly 47 pounds per share.

  • NEW YORK, April 14- After years of responding to shareholder calls for stock buybacks and dividends, major American companies are hearing a different demand from investors: buy growth.

  • Internet stocks were among the day's biggest decliners with Amazon.com down 1.6 percent at $317.76 and Yahoo! The Global X Social Media ETF which includes Groupon Inc and LinkedIn fell 2.5 percent.

  • *Internet stocks tumble; Yahoo shares down nearly 5 pct. Internet stocks were the day's biggest decliners with Amazon.com down 2.8 percent at $314.02, Yahoo! The Global X Social Media ETF which includes Facebook and LinkedIn fell 3.4 percent to $17.91.

  • *Mallinckrodt to buy Questcor for $5.6 bln. *MannKind stumbles; FDA extends drug review date. "We are definitely seeing a little more downside, a continuation from the nasty reversal on Friday," said Ryan Detrick, senior technical strategist at Schaeffer's Investment Research in Cincinnati, Ohio.

  • *MannKind stumbles; FDA extends drug review date. However, other names such as Facebook Inc, up 1 percent to $57.33 and Gilead Sciences Inc, up 0.8 percent at $72.76, were able to reverse initial declines.

  • April 7- Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its lucrative drug to treat multiple sclerosis, Acthar Gel.

  • *Mallinckrodt to buy Questcor for $5.6 bln. *MannKind stumbles; FDA extends review date for insulin treatment. *Earnings season gets under way this week, with earnings expected from financials JPMorgan Chase& Co and Wells Fargo& Co, as well as retailer Bed, Bath& Beyond.

  • April 7- Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its lucrative drug to treat multiple sclerosis, Acthar Gel. This acquisition, Mallinckrodt's second deal in less than two months, highlights its efforts to tap into the fast-growing specialty drugs market.

  • US STOCKS-Futures fall in wake of Friday selloff Monday, 7 Apr 2014 | 7:47 AM ET

    *Mallinckrodt to buy Questcor for $5.6 bln. *MannKind stumbles; FDA extends review date for insulin treatment. *Earnings season gets under way this week, with earnings expected from financials JPMorgan Chase& Co and Wells Fargo& Co, as well as retailer Bed, Bath& Beyond expected.

  • April 7- Specialty pharmaceuticals company Mallinckrodt Plc agreed to buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel.

  • Lightning Round: Splunk, GLD & More Monday, 3 Mar 2014 | 6:38 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Midday movers: Infosys, Sprint, Telsa & more Wednesday, 30 Oct 2013 | 12:41 PM ET

    Take a look at some of Wednesday's midday movers:

  • Lightning Round: GM, Take-Two & More Wednesday, 28 Aug 2013 | 6:45 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Video: Cramer's six stocks in 60 seconds Wednesday, 31 Jul 2013 | 10:41 AM ET

    CNBC's Jim Cramer has six stock calls in sixty seconds (or so.)

  • After-hours buzz: Amgen, Aflac, Symantec & More Tuesday, 30 Jul 2013 | 4:59 PM ET

    Check out which companies are making headlines after the bell Tuesday:

  • After-Hours Buzz: DWA, WU, QCOR & More Tuesday, 30 Apr 2013 | 5:07 PM ET

    Check out which companies are making headlines after the bell Tuesday: